A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy

Ítems similars

• A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors
  per: Chow, Laura Q. M., et al.
  Publicat: (2007)
• A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
  per: Gore, Lia, et al.
  Publicat: (2008)
• A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients
  per: Davies, Janine M., et al.
  Publicat: (2010)
• ICE (ifosfamide, carboplatin, etoposide) with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial
  per: Karuturi, Meghan, et al.
  Publicat: (2015)
• Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
  per: Masayuki Imaya, et al.
  Publicat: (2022-05-01)